Latest news with #HOWARDG
Business Wire
a day ago
- Business
- Business Wire
Abacus Global Management, Inc. (ABL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Abacus Global Management, Inc. ('Abacus' or the 'Company') (NASDAQ: ABL) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ABACUS GLOBAL MANAGEMENT, INC. (ABL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On June 4, 2025, Morpheus Research published a report alleging, among other things, that Abacus uses fraudulent life expectancy data to drive revenues. Specifically, the report alleges 'contrary to Abacus' disclosures to the SEC' Abacus relies heavily on life expectancy ('LE') reports generated by 'AI powered' Lapetus Solutions. The report states former Abacus employees revealed the Company 'built Lapetus LEs into… the proprietary pricing tool that Abacus made' and 'would not gather the other life expectancy info.' The report asserts 'Abacus' reliance on Lapetus to value its portfolio presents a material risk to the $446 million in claimed life settlements on its books as of Q1 2025' because '[t]he indicative value on a Lapetus LE is 50% higher than with the other LE providers.' On this news, Abacus's stock price fell $1.64, or 21.5%, to close at $6.00 per share on June 4, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Abacus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
26-05-2025
- Business
- Business Wire
DoubleVerify Holdings, Inc. (DV) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of DoubleVerify Holdings, Inc. ('DoubleVerify' or the 'Company') (NYSE: DV) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DOUBLEVERIFY HOLDINGS, INC. (DV), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 7, 2024, DoubleVerify released its first quarter 2024 financial results and reduced its 2024 revenue guidance, disclosing that there had been a pullback in customer spending on advertising. On this news, DoubleVerify's stock price fell $11.79, or 38.6%, to close at $18.78 per share on May 8, 2024, thereby injuring investors. Then, on February 27, 2025, DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending. The Company also disclosed that the shift of ad dollars from open exchanges to closed platforms was having a negative impact on the Company. On this news, DoubleVerify's stock price fell $7.83, or 36%, to close at $13.90 per share on February 28, 2025. Then, on March 28, 2025, Adalytics Research, LLC published a report alleging, among other things, that DoubleVerify's web advertisement verification and fraud protection services were ineffective and that its customers were regularly billed for ad impressions served to bots. The same day, The Wall Street Journal reported that DoubleVerify regularly missed detection of nonhuman traffic despite the Company's claims that it helps brands avoid serving ads to nonhuman bot accounts. Contact Us To Participate or Learn More: If you purchased DoubleVerify securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith 3070 Bristol Pike, Suite 112 Bensalem, Pennsylvania 19020 Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
10-05-2025
- Business
- Business Wire
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter's $73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million - $475 million to $250 million - $300 million, a reduction of over 40% at the midpoint. The Company stated it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi ® (lifileucel). Amtagvi was commercially launched in the U.S. in the first half of 2024. On this news, Iovance's stock price fell as much as 52% during intraday trading on May 9, 2025, thereby injuring investors. Contact Us to Participate or Learn More: If you purchased Iovance securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith 3070 Bristol Pike, Suite 112 Bensalem, Pennsylvania 19020 Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
08-05-2025
- Business
- Business Wire
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. ('Myriad' or the 'Company') (NASDAQ: MYGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MYRIAD GENETICS, INC. (MYGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 6, 2025, Myriad released its first quarter 2025 financial results, revealing 'revenue of $196 million declined by 3% year-over-year' and 'pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.' Additionally, the Company announced reduced financial guidance for 2025 'reflecting first quarter 2025 results and the current business outlook.' On this news, Myriad's stock price fell $3.00, or 41.3%, to close at $4.27 per share on May 7, 2025, thereby injuring investors. Contact Us to Participate or Learn More: If you purchased Myriad securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith 3070 Bristol Pike, Suite 112 Bensalem, Pennsylvania 19020 Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
08-05-2025
- Business
- Business Wire
Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Cytokinetics, Incorporated ('Cytokinetics' or the 'Company') (NASDAQ: CYTK) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 1, 2025, Cytokinetics disclosed that the FDA has extended the review period for its cardiac myosin inhibitor drug, aficamten, by three months, citing additional time required to review newly submitted Risk Evaluation and Mitigation Strategy (REMS). The Company further revealed that, 'following pre-NDA discussions with FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for aficamten in oHCM without an accompanying REMS.' On this news, Cytokinetics's stock price fell $5.57, or 12.9%, to close at $37.35 per share on May 2, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Cytokinetics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
